PTC Therapeutics: Multiple Regulatory Submissions Along With Data Cuts [Seeking Alpha]
PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza™ [Yahoo! Finance]
PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza™
PTC Therapeutics to Participate at Upcoming Investor Conferences
PTC Therapeutics, Inc. (NASDAQ: PTCT) was upgraded by analysts at Morgan Stanley from an "underweight" rating to an "equal weight" rating. They now have a $30.00 price target on the stock, up previously from $28.00.